NovMetaPharma Co., Ltd. (XKON:229500)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,520.00
-70.00 (-0.81%)
At close: Apr 18, 2025, 3:30 PM KST
-58.44%
Market Cap 76.99B
Revenue n/a
Net Income n/a
Shares Out 8.96M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,022
Average Volume 8,139
Open 8,790.00
Previous Close 8,590.00
Day's Range 8,430.00 - 8,790.00
52-Week Range 4,505.00 - 10,790.00
Beta 0.43
RSI 54.57
Earnings Date n/a

About NovMetaPharma

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea. The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication. It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 229500
Full Company Profile

News

There is no news available yet.